FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Sell Opinion On Shares Of Imperial Oil Limited

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our target price to CAD145 (from CAD128), implying 9.0x EV to projected 2027 EBITDA, above the historical average. Shares are up ~55% year to date in 2026 and continue to trade at a significant premium relative to peers and its own historical multiple. As a result, while we like IMO's cost improvements and growth potential, we continue to think the upside is largely priced in at this point, and we recommend investors take profits. Valuation is at decade highs relative to peers and 1.7 standard deviations above its 10-year upper band. Share reduction has been aggressive and beneficial to shareholders; however, no shares were repurchased in Q1 2026. Q1 was a particularly weak quarter for IMO, with net income down 27% on a combination of flat production, weaker pricing realizations, a wider differential, and negative foreign exchange impacts. Operational execution of this quality will likely dent the aforementioned premium. We lift our 2026 EPS to CAD9.66 from CAD6.33 and 2027 EPS to CAD8.22 from CAD6.99.

Related Articles

Mining & Metals

TSX Now Up 20 Pts, Was Down 120 Pts Early Monday; Comes After Losses In 6 of Last 7 Full Sessions

$^GSPTSE$.GSPTSE
Australia

Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen

Gyre Therapeutics (GYRE) said Monday it closed the purchase of clinical-stage biopharmaceutical firm Cullgen through an all-stock transaction valued at roughly $300 million.The deal turns the acquired business into a wholly owned unit focusing on therapies for fibrosis and inflammatory diseases, the company said.Former Cullgen chief executive Ying Luo was appointed president, chief executive, and board member of the combined organization, while Ping Zhang will maintain his position as chairman of the board, Gyre Therapeutics said.Price: $7.97, Change: $+0.17, Percent Change: +2.18%

$GYRE
Australia

Update: Wedbush Raises Price Target on Advanced Micro Devices to $400 From $290, Keeps Outperform Rating

(Updates to include Wedbush's commentary).Wedbush raises Advanced Micro Devices (AMD) price target to $400 From $290 ahead of the upcoming Q1 earnings announcement, noting that the company is positioned to beat and guide higher on CPU strength.Continued demand for server compute should provide some insurance moving forward should GPU/AI revenues ramp more slowly than anticipated, analysts Matt Bryson and Antoine Legault wrote in a Monday note.Advanced Micro Devices has an average rating of overweight and mean price target of $312.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $345.87, Change: $-14.67, Percent Change: -4.07%

$AMD